Paul A Northcott

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2979404/publications.pdf

Version: 2024-02-01

163 papers	39,616 citations	6613 79 h-index	5679 162 g-index
169 all docs	169 docs citations	169 times ranked	40880 citing authors

#	Article	IF	Citations
1	Circulating tumor DNA profiling for childhood brain tumors: Technical challenges and evidence for utility. Laboratory Investigation, 2022, 102, 134-142.	3.7	11
2	Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026). Neuro-Oncology, 2022, 24, 1178-1190.	1.2	13
3	Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. Neuro-Oncology, 2022, 24, 1166-1175.	1.2	2
4	Low-coverage whole-genome sequencing of cerebrospinal-fluid-derived cell-free DNA in brain tumor patients. STAR Protocols, 2022, 3, 101292.	1.2	2
5	MEDB-69. Clinical and molecular meta-analysis of three major medulloblastoma clinical trials (ACNS0331, SJMB03, ACNS0332) uncovers novel strategies to improve risk-stratified therapy. Neuro-Oncology, 2022, 24, i122-i122.	1.2	1
6	INSP-09. Using genetically engineered mouse models and patient-derived orthotopic xenografts to develop new therapies for pediatric brain tumors.. Neuro-Oncology, 2022, 24, i188-i188.	1.2	0
7	MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. Neuro-Oncology, 2022, 24, i124-i125.	1.2	1
8	The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors. Nature Communications, 2022, 13, .	12.8	16
9	Deconstructing Sonic Hedgehog Medulloblastoma: Molecular Subtypes, Drivers, and Beyond. Trends in Genetics, 2021, 37, 235-250.	6.7	40
10	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. Acta Neuropathologica, 2021, 141, 771-785.	7.7	44
11	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 807-821.	1.6	40
12	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). Journal of Clinical Oncology, 2021, 39, 822-835.	1.6	106
13	Depletion of kinesin motor KIF20A to target cell fate control suppresses medulloblastoma tumour growth. Communications Biology, 2021, 4, 552.	4.4	5
14	Medulloblastoma uses GABA transaminase to survive in the cerebrospinal fluid microenvironment and promote leptomeningeal dissemination. Cell Reports, 2021, 35, 109302.	6.4	19
15	Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. Nature Communications, 2021, 12, 4089.	12.8	27
16	Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. Journal of Clinical Oncology, 2021, 39, 2685-2697.	1.6	91
17	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	7.7	34
18	A genetic mouse model with postnatalNf1andp53loss recapitulates the histology and transcriptome of human malignant peripheral nerve sheath tumor. Neuro-Oncology Advances, 2021, 3, vdab129.	0.7	3

#	Article	IF	Citations
19	Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma. JAMA Oncology, 2021, 7, 1313.	7.1	61
20	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. Cancer Cell, 2021, 39, 1519-1530.e4.	16.8	64
21	BIOM-36. SERIAL ASSESSMENT OF MEASURABLE RESIDUAL DISEASE IN MEDULLOBLASTOMA LIQUID BIOPSIES. Neuro-Oncology, 2021, 23, vi18-vi19.	1.2	0
22	Germline GPR161 Mutations Predispose to Pediatric Medulloblastoma. Journal of Clinical Oncology, 2020, 38, 43-50.	1.6	50
23	SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors. Neuro-Oncology, 2020, 22, 785-796.	1.2	18
24	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. Acta Neuropathologica, 2020, 139, 259-271.	7.7	36
25	Medulloblastomics revisited: biological and clinical insights from thousands of patients. Nature Reviews Cancer, 2020, 20, 42-56.	28.4	147
26	Medulloblastoma genomics in the modern molecular era. Brain Pathology, 2020, 30, 679-690.	4.1	39
27	Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Childrenâ€™s Oncology Group (ACNS1221). Journal of Clinical Oncology, 2020, 38, 223-231.	1.6	40
28	WNT-activated embryonal tumors of the pineal region: ectopic medulloblastomas or a novel pineoblastoma subgroup?. Acta Neuropathologica, 2020, 140, 595-597.	7.7	7
29	Functional loss of a noncanonical BCORâ€“PRC1.1 complex accelerates SHH-driven medulloblastoma formation. Genes and Development, 2020, 34, 1161-1176.	5.9	16
30	Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource. Acta Neuropathologica, 2020, 140, 209-225.	7.7	45
31	DDX3X Suppresses the Susceptibility of Hindbrain Lineages to Medulloblastoma. Developmental Cell, 2020, 54, 455-470.e5.	7.0	47
32	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. Nature, 2020, 580, 396-401.	27.8	94
33	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	6.5	24
34	Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen. Neuro-Oncology, 2020, 22, 1873-1881.	1.2	12
35	Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma. Cell Reports, 2020, 30, 454-464.e5.	6.4	26
36	Resolving medulloblastoma cellular architecture by single-cell genomics. Nature, 2019, 572, 74-79.	27.8	273

#	Article	IF	Citations
37	Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma. Nature Communications, 2019, 10, 332.	12.8	55
38	Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma. Nature Communications, 2019, 10, 2410.	12.8	99
39	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. Acta Neuropathologica, 2019, 138, 309-326.	7.7	180
40	Medulloblastoma. Nature Reviews Disease Primers, 2019, 5, 11.	30.5	376
41	scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy. Nature Communications, 2019, 10, 5829.	12.8	77
42	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. Cancer Cell, 2019, 35, 95-110.e8.	16.8	65
43	The landscape of genomic alterations across childhood cancers. Nature, 2018, 555, 321-327.	27.8	1,068
44	Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. Acta Neuropathologica, 2018, 135, 635-638.	7.7	17
45	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. Nature, 2018, 553, 101-105.	27.8	170
46	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
47	NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma. Cancer Cell, 2018, 33, 435-449.e6.	16.8	52
48	Bithalamic gliomas may be molecularly distinct from their unilateral highâ€grade counterparts. Brain Pathology, 2018, 28, 112-120.	4.1	26
49	Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic. Cancer, 2018, 124, 4168-4180.	4.1	64
50	A biobank of patient-derived pediatric brain tumor models. Nature Medicine, 2018, 24, 1752-1761.	30.7	124
51	A Single-Cell Transcriptional Atlas of the Developing Murine Cerebellum. Current Biology, 2018, 28, 2910-2920.e2.	3.9	158
52	Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2018, 34, 396-410.e8.	16.8	146
53	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. Lancet Oncology, The, 2018, 19, 768-784.	10.7	151
54	MLL4 Is Required to Maintain Broad H3K4me3 Peaks and Super-Enhancers at Tumor Suppressor Genes. Molecular Cell, 2018, 70, 825-841.e6.	9.7	123

#	Article	IF	Citations
55	Proteomic analysis of Medulloblastoma reveals functional biology with translational potential. Acta Neuropathologica Communications, 2018, 6, 48.	5.2	35
56	UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs. Nature Genetics, 2018, 50, 883-894.	21.4	117
57	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. Lancet Oncology, The, 2018, 19, 785-798.	10.7	268
58	Spatial heterogeneity in medulloblastoma. Nature Genetics, 2017, 49, 780-788.	21.4	112
59	Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma. Cell Reports, 2017, 18, 2907-2917.	6.4	61
60	Chd7 is indispensable for mammalian brain development through activation of a neuronal differentiation programme. Nature Communications, 2017, 8, 14758.	12.8	118
61	DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. Acta Neuropathologica, 2017, 134, 965-967.	7.7	38
62	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	27.8	787
63	Keeping it real to kill glioblastoma. Nature, 2017, 547, 291-292.	27.8	13
64	Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nature Genetics, 2017, 49, 65-74.	21.4	326
65	Genomic Analysis of Childhood Brain Tumors: Methods for Genome-Wide Discovery and Precision Medicine Become Mainstream. Journal of Clinical Oncology, 2017, 35, 2346-2354.	1.6	25
66	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathologica, 2016, 131, 821-831.	7.7	478
67	Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. Journal of Clinical Oncology, 2016, 34, 4151-4160.	1.6	121
68	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. Nature, 2016, 530, 57-62.	27.8	318
69	Divergent clonal selection dominates medulloblastoma at recurrence. Nature, 2016, 529, 351-357.	27.8	266
70	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	16.8	438
71	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	28.9	702
72	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274

#	Article	IF	Citations
73	Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas. Acta Neuropathologica, 2016, 131, 299-307.	7.7	38
74	Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress. Oncotarget, 2016, 7, 28169-28182.	1.8	62
75	Norrin/Frizzled4 signalling in the preneoplastic niche blocks medulloblastoma initiation. ELife, 2016, 5, .	6.0	21
76	A cellâ€based model system links chromothripsis with hyperploidy. Molecular Systems Biology, 2015, 11, 828.	7.2	118
77	Deep Sequencing Identifies IDH1 R132S Mutation in Adult Medulloblastoma. Journal of Clinical Oncology, 2015, 33, e27-e31.	1.6	18
78	Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. Lancet Oncology, The, 2015, 16, e293-e302.	10.7	72
79	Medulloblastoma subgroups remain stable across primary and metastatic compartments. Acta Neuropathologica, 2015, 129, 449-457.	7.7	80
80	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathologica, 2015, 129, 669-678.	7.7	277
81	Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. Nature Communications, 2015, 6, 7391.	12.8	244
82	Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas. Journal of Neuro-Oncology, 2015, 123, 1-13.	2.9	13
83	Foretinib Is Effective Therapy for Metastatic Sonic Hedgehog Medulloblastoma. Cancer Research, 2015, 75, 134-146.	0.9	51
84	Proteomic profiling of high risk medulloblastoma reveals functional biology. Oncotarget, 2015, 6, 14584-14595.	1.8	20
85	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. Acta Neuropathologica Communications, 2014, 2, 174.	5.2	37
86	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothened Inhibition. Cancer Cell, 2014, 25, 393-405.	16.8	627
87	Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. Acta Neuropathologica, 2014, 128, 137-149.	7.7	125
88	Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. Nature, 2014, 510, 537-541.	27.8	378
89	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. Acta Neuropathologica, 2014, 128, 279-289.	7.7	191
90	The Shh Receptor Boc Promotes Progression of Early Medulloblastoma to Advanced Tumors. Developmental Cell, 2014, 31, 34-47.	7.0	43

#	Article	IF	Citations
91	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	1.6	263
92	Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma. Nature, 2014, 511, 428-434.	27.8	520
93	Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts. Acta Neuropathologica, 2014, 128, 123-136.	7.7	54
94	Quiescent Sox2+ Cells Drive Hierarchical Growth and Relapse in Sonic Hedgehog Subgroup Medulloblastoma. Cancer Cell, 2014, 26, 33-47.	16.8	241
95	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. Nature Genetics, 2013, 45, 927-932.	21.4	674
96	Signatures of mutational processes in human cancer. Nature, 2013, 500, 415-421.	27.8	8,060
97	Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathologica, 2013, 125, 913-916.	7.7	244
98	DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. Acta Neuropathologica, 2013, 125, 359-371.	7.7	133
99	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. Acta Neuropathologica, 2013, 125, 373-384.	7.7	169
100	Hypermutation of the Inactive X Chromosome Is a Frequent Event in Cancer. Cell, 2013, 155, 567-581.	28.9	67
101	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathologica, 2013, 126, 907-915.	7.7	254
102	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.	10.7	307
103	Targeting Sonic Hedgehog-Associated Medulloblastoma through Inhibition of Aurora and Polo-like Kinases. Cancer Research, 2013, 73, 6310-6322.	0.9	52
104	Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children. Cancer Research, 2013, 73, 6734-6744.	0.9	79
105	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. Cancer Cell, 2013, 24, 660-672.	16.8	633
106	The Role of Chromatin Remodeling in Medulloblastoma. Brain Pathology, 2013, 23, 193-199.	4.1	37
107	MyoD Is a Tumor Suppressor Gene in Medulloblastoma. Cancer Research, 2013, 73, 6828-6837.	0.9	21
108	Canonical <scp>TGF</scp>â€Î² Pathway Activity Is a Predictor of <scp>SHH</scp>â€Driven Medulloblastoma Survival and Delineates Putative Precursors in Cerebellar Development. Brain Pathology, 2013, 23, 178-191.	4.1	26

#	Article	IF	Citations
109	Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. Neuro-Oncology, 2013, 15, 1644-1651.	1.2	73
110	The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. Cell, 2013, 153, 1064-1079.	28.9	348
111	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	7.7	146
112	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. Journal of Clinical Oncology, 2013, 31, 2927-2935.	1.6	381
113	Intertumoral and Intratumoral Heterogeneity as a Barrier for Effective Treatment of Medulloblastoma. Neurosurgery, 2013, 60, 57-63.	1.1	13
114	Coverage Bias and Sensitivity of Variant Calling for Four Whole-genome Sequencing Technologies. PLoS ONE, 2013, 8, e66621.	2.5	74
115	CXCR4 Activation Defines a New Subgroup of Sonic Hedgehogâ€“Driven Medulloblastoma. Cancer Research, 2012, 72, 122-132.	0.9	58
116	Functional Genomics Identifies Drivers of Medulloblastoma Dissemination. Cancer Research, 2012, 72, 4944-4953.	0.9	44
117	Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. Genes and Development, 2012, 26, 1780-1796.	5.9	68
118	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature, 2012, 488, 49-56.	27.8	761
119	Medulloblastomics: the end of the beginning. Nature Reviews Cancer, 2012, 12, 818-834.	28.4	560
120	Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathologica, 2012, 123, 615-626.	7.7	318
121	LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). Acta Neuropathologica, 2012, 124, 875-881.	7.7	115
122	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature, 2012, 488, 106-110.	27.8	675
123	Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. Cell, 2012, 148, 59-71.	28.9	743
124	Molecular subgroups of medulloblastoma. Expert Review of Neurotherapeutics, 2012, 12, 871-884.	2.8	142
125	The RNA-Binding Protein Musashi1 Affects Medulloblastoma Growth via a Network of Cancer-Related Genes and Is an Indicator of Poor Prognosis. American Journal of Pathology, 2012, 181, 1762-1772.	3.8	73
126	The clinical implications of medulloblastoma subgroups. Nature Reviews Neurology, 2012, 8, 340-351.	10.1	261

#	Article	IF	Citations
127	Clonal selection drives genetic divergence of metastatic medulloblastoma. Nature, 2012, 482, 529-533.	27.8	376
128	The Epigenetics of Brain Tumors. Methods in Molecular Biology, 2012, 863, 139-153.	0.9	38
129	Dissecting the genomic complexity underlying medulloblastoma. Nature, 2012, 488, 100-105.	27.8	765
130	Targeting the enhancer of zeste homologue 2 in medulloblastoma. International Journal of Cancer, 2012, 131, 1800-1809.	5.1	71
131	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. Acta Neuropathologica, 2012, 123, 515-527.	7.7	66
132	Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathologica, 2012, 123, 465-472.	7.7	1,536
133	MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. Acta Neuropathologica, 2012, 123, 529-538.	7.7	60
134	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathologica, 2012, 123, 473-484.	7.7	863
135	Subgroup-specific alternative splicing in medulloblastoma. Acta Neuropathologica, 2012, 123, 485-499.	7.7	28
136	An Animal Model of MYC-Driven Medulloblastoma. Cancer Cell, 2012, 21, 155-167.	16.8	267
137	Distinct Neural Stem Cell Populations Give Rise to Disparate Brain Tumors in Response to N-MYC. Cancer Cell, 2012, 21, 601-613.	16.8	177
138	Adult Medulloblastoma Comprises Three Major Molecular Variants. Journal of Clinical Oncology, 2011, 29, 2717-2723.	1.6	215
139	The Genetic Landscape of the Childhood Cancer Medulloblastoma. Science, 2011, 331, 435-439.	12.6	652
140	FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. Cancer Genetics, 2011, 204, 577-588.	0.4	50
141	Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. Cancer Cell, 2011, 20, 143-157.	16.8	494
142	PCDH10 is a candidate tumour suppressor gene in medulloblastoma. Child's Nervous System, 2011, 27, 1243-1249.	1.1	21
143	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathologica, 2011, 122, 231-240.	7.7	195
144	FSTL5 Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma. Journal of Clinical Oncology, 2011, 29, 3852-3861.	1.6	143

#	Article	IF	Citations
145	Medulloblastoma Comprises Four Distinct Molecular Variants. Journal of Clinical Oncology, 2011, 29, 1408-1414.	1.6	1,131
146	Mouse models of medulloblastoma. Chinese Journal of Cancer, 2011, 30, 442-449.	4.9	38
147	The Genetics of Pediatric Brain Tumors. Current Neurology and Neuroscience Reports, 2010, 10, 215-223.	4.2	69
148	Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature, 2010, 466, 632-636.	27.8	324
149	Role of LIM and SH3 Protein 1 (LASP1) in the Metastatic Dissemination of Medulloblastoma. Cancer Research, 2010, 70, 8003-8014.	0.9	62
150	Pleiotropic role forMYCNin medulloblastoma. Genes and Development, 2010, 24, 1059-1072.	5.9	146
151	Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. Neurosurgical Focus, 2010, 28, E6.	2.3	48
152	Silencing of Thrombospondin-1 Is Critical for Myc-Induced Metastatic Phenotypes in Medulloblastoma. Cancer Research, 2010, 70, 8199-8210.	0.9	54
153	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth. Clinical Cancer Research, 2010, 16, 3240-3252.	7.0	175
154	Genetic and Epigenetic Inactivation of Kruppel-like Factor 4 in Medulloblastoma. Neoplasia, 2010, 12, 20-27.	5.3	69
155	Calculating a cure for cancer: managing medulloblastoma MATH1-ematically. Expert Review of Neurotherapeutics, 2010, 10, 1489-1492.	2.8	7
156	OTX2 Is Critical for the Maintenance and Progression of Shh-Independent Medulloblastomas. Cancer Research, 2010, 70, 181-191.	0.9	104
157	MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma. PLoS ONE, 2009, 4, e4998.	2.5	233
158	Normal and oncogenic roles for microRNAs in the developing brain. Cell Cycle, 2009, 8, 4049-4054.	2.6	30
159	YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. Genes and Development, 2009, 23, 2729-2741.	5.9	332
160	Tuberous Sclerosis Complex Suppression in Cerebellar Development and Medulloblastoma: Separate Regulation of Mammalian Target of Rapamycin Activity and p27Kip1 Localization. Cancer Research, 2009, 69, 7224-7234.	0.9	37
161	Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. Nature Genetics, 2009, 41, 465-472.	21.4	391
162	The miR-17/92 Polycistron Is Up-regulated in Sonic Hedgehogâ€“Driven Medulloblastomas and Induced by N-myc in Sonic Hedgehogâ€“Treated Cerebellar Neural Precursors. Cancer Research, 2009, 69, 3249-3255.	0.9	273

#	Article	IF	Citations
163	An Epigenetic Genome-Wide Screen Identifies SPINT2 as a Novel Tumor Suppressor Gene in Pediatric Medulloblastoma. Cancer Research, 2008, 68, 9945-9953.	0.9	95